Idera receives U.S. patent for drug candidate to treat autoimmune diseases
IMO-8400, which is an antagonist of Toll-like receptors seven, eight and nine, is being evaluated in a Phase II trial in patients with moderate-to-severe plaque psoriasis. Patent number 8,486,908 protects both composition of matter and method of use for IMO-8400.
"IMO-8400 is a first-in-class antagonist, and we are pleased that the U.S. Patent and Trademark Office recognizes the novelty, utility, and applications of this compound," Steven Ritter, the vice president of Intellectual Property and Business Affairs at Idera, said. "Based on its ability to inhibit the inflammation pathways linked to TLRs seven, eight and nine, IMO-8400 provides a novel approach to the treatment of autoimmune and inflammatory diseases as well as other potential indications."
Idera has eight issued patents related to TLR antagonists and 29 pending patent applications in countries throughout the world. The patents and patent applications cover methods of use and compositions of matter.
Idera said that in addition to use in the treatment of plaque psoriasis, IMO-8400 could have therapeutic potential in various other indications.
Additionally, Idera has a collaboration with Merck & Co. to develop vaccine adjuvants for Alzheimer's disease, infectious diseases and cancer.